Data sources

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Paper citation network

Psilocybin and psilocin regulate microglial immunomodulation and support neuroplasticity via serotonergic and AhR signaling

Laabi Salma, LeMmon Claire, Vogel Callie, Chacon Mariana, Jimenez Victor M.

Publication record · Explore literature

Public tracker catalogue and stored structured reference metadata. External references may have identifiers only. No live external citation lookup is performed.

References — this paper cites (136)

  1. Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases. 2024-06-01 · Expand citations
  2. Deciphering psilocybin: Cytotoxicity, anti-inflammatory effects, and mechanistic insights. 2024-03-30 · Expand citations
  3. Psilocybin for the treatment of Alzheimer's disease. 2024-01-01 · Expand citations
  4. Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study. 2023-11-01 · Expand citations
  5. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. 2023-09-01 · Expand citations
  6. Anti-Inflammatory Effects of Serotonin Receptor and Transient Receptor Potential Channel Ligands in Human Small Intestinal Epithelial Cells. 2023-08-15 · Expand citations
  7. Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders. 2023-06-15 · Expand citations
  8. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. 2023-06-01 · Expand citations
  9. The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice. 2023-03-14 · Expand citations
  10. Inhibition of Microglial GSK3β Activity Is Common to Different Kinds of Antidepressants: A Proposal for an In Vitro Screen to Detect Novel Antidepressant Principles. 2023-03-07 · Expand citations
  11. Towards an understanding of psychedelic-induced neuroplasticity. 2023-01-01 · Expand citations
  12. From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders. 2022-07-01 · Expand citations
  13. Beating pain with psychedelics: Matter over mind? 2022-03-01 · Expand citations
  14. Psilocybin, a Naturally Occurring Indoleamine Compound, Could Be Useful to Prevent Suicidal Behaviors. 2021-11-24 · Expand citations
  15. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. 2021-08-18 · Expand citations
  16. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. 2021-05-01 · Expand citations
  17. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. 2021-04-27 · Expand citations
  18. Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin. 2021-04-01 · Expand citations
  19. A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT Receptor Density in the Pig Brain. 2021-01-15 · Expand citations
  20. Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells. 2021-01-01 · Expand citations
  21. Studies on Psilocybin Drug Derivatives Against SARS-CoV-2 and Cytokine Storm of Human Interleukin-6 Receptor. 2021-01-01 · Expand citations
  22. Effects and safety of Psilocybe cubensis and Panaeolus cyanescens magic mushroom extracts on endothelin-1-induced hypertrophy and cell injury in cardiomyocytes. 2020-12-18 · Expand citations
  23. Psilocybin: from ancient magic to modern medicine. 2020-10-01 · Expand citations
  24. Reviewing the Potential of Psychedelics for the Treatment of PTSD. 2020-06-24 · Expand citations
  25. Emotions and brain function are altered up to one month after a single high dose of psilocybin. 2020-02-10 · Expand citations
  26. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels 2019-06-01 · Expand citations
  27. Psychedelics as anti-inflammatory agents. 2018-08-01 · Expand citations
  28. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. 2018-02-01 · Expand citations
  29. Long-term follow-up of psilocybin-facilitated smoking cessation. 2017-01-01 · Expand citations
  30. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. 2016-07-01 · Expand citations
  31. Psychedelics. 2016-04-01 · Expand citations
  32. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. 2015-03-01 · Expand citations
  33. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. 2014-11-01 · Expand citations
  34. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. 2006-11-01 · Expand citations
  35. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. 2006-08-01 · Expand citations
  36. 10.1002/glia.22772
  37. 10.1002/glia.22805
  38. 10.1002/glia.22894
  39. 10.1002/glia.23568
  40. 10.1002/glia.23918
  41. 10.1007/s00406-021-01334-z
  42. 10.1007/s00432-022-04365-8
  43. 10.1007/s12031-020-01506-x
  44. 10.1007/s12035-016-0297-1
  45. 10.1016/b978-0-444-64125-0.00034-7
  46. 10.1016/j.bbi.2011.12.002
  47. 10.1016/j.bbi.2011.12.011
  48. 10.1016/j.bbi.2021.12.026
  49. 10.1016/j.bcp.2008.08.031
  50. 10.1016/j.cell.2013.11.030
  51. 10.1016/j.celrep.2018.05.022
  52. 10.1016/j.celrep.2023.112203
  53. 10.1016/j.ebiom.2021.103227
  54. 10.1016/j.neuropharm.2014.03.013
  55. 10.1016/j.pharmthera.2011.03.008
  56. 10.1016/j.phrs.2020.105030
  57. 10.1016/j.phrs.2024.107322
  58. 10.1016/j.tins.2012.11.007
  59. 10.1016/s0022-3565(25)12956-x
  60. 10.1016/s0893-133x(01)00405-5
  61. 10.1016/s0896-6273(01)00561-x
  62. 10.1016/s1097-2765(04)00216-3
  63. 10.1021/acs.chemrestox.8b00371
  64. 10.1021/acschemneuro.7b00309
  65. 10.1038/370223a0
  66. 10.1038/374085a0
  67. 10.1038/384641a0
  68. 10.1038/emm.2006.40
  69. 10.1038/gene.2015.37
  70. 10.1038/nm.4106
  71. 10.1038/nn1472
  72. 10.1038/onc.2011.438
  73. 10.1038/s41380-021-01377-7
  74. 10.1038/s41467-023-44016-1
  75. 10.1038/s41586-018-0119-x
  76. 10.1038/s41598-018-20173-y
  77. 10.1038/s41598-022-20164-0
  78. 10.1038/sj.bjp.0703357
  79. 10.1046/j.1432-1033.2002.03157.x
  80. 10.1073/pnas.0402851101
  81. 10.1073/pnas.0907502106
  82. 10.1074/jbc.271.5.2373
  83. 10.1074/jbc.m203298200
  84. 10.1074/jbc.m206237200
  85. 10.1093/cercor/bhaa062
  86. 10.1093/oxfordjournals.jbchem.a021812
  87. 10.1093/toxsci/kfq217
  88. 10.1100/2012/823493
  89. 10.1111/ejn.13959
  90. 10.1124/jpet.108.143461
  91. 10.1124/pr.118.015552
  92. 10.1126/science.1110647
  93. 10.1126/science.1232808
  94. 10.1126/science.aad8373
  95. 10.1126/science.aaz2288
  96. 10.1146/annurev-immunol-051116-052358
  97. 10.1159/000363036
  98. 10.1161/jaha.117.006810
  99. 10.1172/jci43992
  100. 10.1177/1179069518800508
  101. 10.1182/bloodadvances.2023010169
  102. 10.1186/1742-2094-10-16
  103. 10.1186/s12868-023-00809-0
  104. 10.1186/s12964-023-01058-8
  105. 10.1186/s12974-020-01887-1
  106. 10.1186/s12974-020-01922-1
  107. 10.1186/s12974-020-02069-9
  108. 10.1186/s12974-022-02492-0
  109. 10.1186/s12974-022-02651-3
  110. 10.1186/s12974-023-02764-3
  111. 10.1371/journal.pbio.1000527
  112. 10.1371/journal.pone.0009019
  113. 10.1371/journal.pone.0075426
  114. 10.1515/revneuro-2016-0017
  115. 10.1523/eneuro.0088-18.2018
  116. 10.1523/jneurosci.0367-19.2019
  117. 10.1523/jneurosci.17-08-02785.1997
  118. 10.1523/jneurosci.2539-20.2021
  119. 10.1523/jneurosci.3959-04.2005
  120. 10.1523/jneurosci.4346-04.2005
  121. 10.2174/138955712800959152
  122. 10.3389/fimmu.2022.1011129
  123. 10.3389/fncel.2015.00054
  124. 10.3389/fncel.2022.980722
  125. 10.3389/fncel.2023.1188672
  126. 10.3389/fneur.2022.917527
  127. 10.3389/ftox.2022.775010
  128. 10.3390/biomedicines11020461
  129. 10.3390/cells10040718
  130. 10.3390/ijms19123753
  131. 10.3390/ijms19123851
  132. 10.3390/ijms21207777
  133. 10.3390/ijms22020757
  134. 10.3390/ijms23010288
  135. 10.4049/jimmunol.1700896
  136. 10.4103/1673-5374.322423

Cited by — these papers cite this paper (3)

  1. Psilocybin and Chronic Neuropathic and Centralized Pain: Converging Mechanisms in Central Sensitization, Neuroplasticity, and Network Organization 2026-09-11 · Expand citations
  2. Efficacy of psilocybin on death anxiety in terminal patients: a narrative review 2025-11-30 · Expand citations
  3. Multianalytical Investigation of Psilocybe cubensis Mushrooms: Physicochemical Characterization and Biological Evaluation of Psilocybin and Psilocin Compounds 2025-09-30 · Expand citations